It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company just changed the game entirely. The company bringing what I call "QaaS" to the masses could dominate the industry and make an absolute killing.

It's easy to see why this company is being called "the Next Nvidia."

Bankole A. Johnson net worth and biography

Bankole Johnson Biography and Net Worth

Insider of Adial Pharmaceuticals

Bankole Johnson is 60, he's been the Chief Medical Officer of Adial Pharmaceuticals since 2019. There are 3 older and 5 younger executives at Adial Pharmaceuticals. The oldest executive at Adial Pharmaceuticals, Inc. is James Newman, 77, who is the Independent Director.

What is Bankole A. Johnson's net worth?: The estimated net worth of Bankole A. Johnson is at least $44.10 as of April 6th, 2021. Dr. Johnson owns 42 shares of Adial Pharmaceuticals stock worth more than $44 as of December 24th. This net worth evaluation does not reflect any other assets that Dr. Johnson may own. Additionally, Dr. Johnson receives an annual salary of $435,000.00 as Insider at Adial Pharmaceuticals. Learn More about Bankole A. Johnson's net worth.
How old is Bankole A. Johnson?: Dr. Johnson is currently 64 years old. There are 3 older executives and no younger executives at Adial Pharmaceuticals. Learn More on Bankole A. Johnson's age.
What is Bankole A. Johnson's salary?: As the Insider of Adial Pharmaceuticals, Inc., Dr. Johnson earns $435,000.00 per year. The highest earning executive at Adial Pharmaceuticals is Mr. Cary John Claiborne MBA, CEO, President & Director, who commands a salary of $728,310.00 per year. Learn More on Bankole A. Johnson's salary.
How do I contact Bankole A. Johnson?: The corporate mailing address for Dr. Johnson and other Adial Pharmaceuticals executives is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. Adial Pharmaceuticals can also be reached via phone at (434) 422-9800 and via email at [email protected]. Learn More on Bankole A. Johnson's contact information.
Has Bankole A. Johnson been buying or selling shares of Adial Pharmaceuticals?: Bankole A. Johnson has not been actively trading shares of Adial Pharmaceuticals over the course of the past ninety days. Most recently, Bankole A. Johnson sold 6,000 shares of the business's stock in a transaction on Tuesday, April 6th. The shares were sold at an average price of $62.50, for a transaction totalling $375,000.00. Following the completion of the sale, the insider now directly owns 42 shares of the company's stock, valued at $2,625. Learn More on Bankole A. Johnson's trading history.
Who are Adial Pharmaceuticals' active insiders?: Adial Pharmaceuticals' insider roster includes Bankole Johnson (Insider), James Newman, Jr. (Director), and William Stilley, III (CEO). Learn More on Adial Pharmaceuticals' active insiders.

Bankole A. Johnson Insider Trading History at Adial Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2021	Sell	6,000	$62.50	$375,000.00	42
12/12/2019	Sell	6,000	$25.00	$150,000.00	14,042
3/29/2019	Buy	2,924	$82.25	$240,499.00

Bankole A. Johnson Buying and Selling Activity at Adial Pharmaceuticals

Adial Pharmaceuticals Company Overview

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Today's Range

Now: $1.05

$1.01

$1.05

50 Day Range

MA: $1.06

$0.95

$1.23

2 Week Range

Now: $1.05

$0.77

$4.17

Volume

62,597 shs

Average Volume

2,415,887 shs

Market Capitalization

$6.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Is Jeff Bezos Crowning the Next Nvidia?

From InvestorPlace | Ad